| Olivera Janjic Quitkin, MD | |
|
333 Borthwick Ave, Portsmouth Anesthesia Associates, Portsmouth, NH 03801-7128 | |
| (603) 436-5110 | |
| Not Available |
| Full Name | Olivera Janjic Quitkin |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 27 Years |
| Location | 333 Borthwick Ave, Portsmouth, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053484865 | NPI | - | NPPES |
| 034145800 | Medicaid | DC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD 33502 (District Of Columbia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Portsmouth Regional Hospital | Portsmouth, NH | Hospital |
| Frisbie Memorial Hospital | Rochester, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Portsmouth Anesthesia Associates Pa | 6002855327 | 44 |
| Stratham Anesthesia Associates Pllc | 7416007950 | 13 |
News Archive
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
› Verified 8 days ago
| Entity Name | Portsmouth Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568584290 PECOS PAC ID: 6002855327 Enrollment ID: O20050427000080 |
News Archive
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
› Verified 8 days ago
| Entity Name | Stratham Anesthesia Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346480639 PECOS PAC ID: 7416007950 Enrollment ID: O20090604000241 |
News Archive
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Olivera Janjic Quitkin, MD 333 Borthwick Ave, Portsmouth Anesthesia Associates, Portsmouth, NH 03801-7128 Ph: (603) 436-5110 | Olivera Janjic Quitkin, MD 333 Borthwick Ave, Portsmouth Anesthesia Associates, Portsmouth, NH 03801-7128 Ph: (603) 436-5110 |
News Archive
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product teduglutide (Revestive) as a once-daily treatment for adult patients with short bowel syndrome (SBS).
RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced the presentation of new preclinical data from its advanced RNAi therapeutic platform at its Annual Investor Event held in New York City on Monday, October 5, 2009.
Durata Therapeutics today announced results from its QT study of the company's lead product candidate, dalbavancin. Dalbavancin is currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of an important clinical study on heel and foot pain, which was led by David Genecov, M.D. FACS FAAP.
› Verified 8 days ago
Michael N Baker, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 100 Griffin Road, Suite B, Portsmouth, NH 03801 Phone: 603-431-8819 Fax: 603-427-2540 | |
Dr. Peter Chiayen Huang, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Andrew Joseph Kulesza, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Trevor B Emory, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Richard James Duffy, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 333 Borthwick Ave, Portsmouth, NH 03801 Phone: 603-436-5110 | |
Dr. Robert Lehn, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 14 Manchester Sq, Portsmouth, NH 03801 Phone: 603-766-8500 Fax: 603-766-8550 |